The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).
 
Neeraj Agarwal
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Exelixis; Foundation One Inc; Genentech/Roche; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pharmacyclics
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Neal D. Shore
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Curtis Dunshee
Consulting or Advisory Role - Pfizer
Research Funding - Astellas Medivation (Inst); AstraZeneca (Inst); BHR Pharma (Inst); Churchill Pharmaceuticals (Inst); Dendreon (Inst); Eleven Biotherapeutics (Inst); Exact Sciences (Inst); Ferring (Inst); Janssen Oncology (Inst); Myovant Sciences (Inst); pfizer (Inst); Siemens (Inst); TesoRX Pharmaceuticals (Inst)
 
Lawrence Ivan Karsh
Stock and Other Ownership Interests - Swan Valley Medical
Honoraria - Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer
Consulting or Advisory Role - 3D Biopsy; Abbvie; Astellas Pharma; Augmenix; Bayer; Dendreon; Ferring; Janssen; Pfizer; Precision Biopsy; Spectrum Pharmaceuticals
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer
Research Funding - Astellas Pharma (Inst); Augmenix (Inst); Bayer (Inst); CU Optics (Inst); Dendreon (Inst); Exact Sciences (Inst); Ferring (Inst); FKD Therapies (Inst); Genomic Health (Inst); Janssen (Inst); Merck (Inst); Myovant Sciences (Inst); Nucleix (Inst); Nymox (Inst); OPKO Biologics (Inst); Pfizer (Inst); Pharmatech/Veru (Inst); Precision Biopsy (Inst); PrecisionMed (Inst); Roche (Inst); Siemens (Inst); Spectrum Pharmaceuticals (Inst); Urogen pharma (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; dendreon; Janssen; Pfizer; Spectrum Pharmaceuticals
 
Beth Sullivan
Employment - pfizer
Stock and Other Ownership Interests - pfizer
 
Nicola Di Santo
Employment - pfizer
Stock and Other Ownership Interests - pfizer
 
Mohamed Elmeliegy
Employment - Novartis; Pfizer; Walgreens (I)
Stock and Other Ownership Interests - Pfizer
 
Xun Lin
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Ruben G.W. Quek
Employment - Pfizer
Stock and Other Ownership Interests - Amgen; Pfizer
 
Akos Gabor Czibere
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
Patents, Royalties, Other Intellectual Property - Various patents through employment at Merrimack.
 
Karim Fizazi
Honoraria - Astellas Pharma; Janssen; Merck; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Curevac; ESSA; Janssen Oncology; Orion; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Amgen; Janssen